Moderna’s personalized mRNA vaccine cuts the risk of melanoma returning by 42%
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
In a phase III trial, personalized mRNA vaccine intismeran reduced the risk of melanoma returning or patients dying by 42% when combined with immunotherapy after tumour-removal surgery. Developers Moderna and Merck released the key results after an online leak on 22 October.
Continue in the app — vote & join in ➔Source: Nature News · via ahirlevel.hu